Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.
Industries BiopharmaBiotechnologyHealth CareLife ScienceHeadquarters Regions European Union (EU), Europe, Middle East, and Africa (EMEA) Founded Date 2012 Founders Pierre Belichard, Stanislav Dusko EHRLICH Operating Status Active Last Funding Type Venture - Series Unknown Legal Name ENTEROME SA
Company Type For Profit
Contact Email media@enterome.com Phone Number 33 1 76 21 58 19
Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or
actions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.